Genedrive PLC - Trading Update
genedrive plc
("genedrive" or the "Company")
Trading Update
- Strong commercial progress and poised for continued growth in the next 12 months
- FY26 expected revenue of
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today provides an unaudited trading update for the financial year ended
Dr
"genedrive is in its strongest commercial and operational position to date. Supported by a strengthened financial position, expanding market opportunities and a growing body of real-world evidence, we are well positioned to build on this foundation, accelerate commercial adoption in the next 12 months and create sustainable long-term value for shareholders."
Genedrive® MT-RNR1
· Completion of the National Institute for Health and Care Research ("NIHR") and Office for Life Sciences ("OLS") funded National Institute for Health and Care Excellence ("NICE") MT-RNR1 Evidence-generation programme, with NICE expected to publish its final guidance around
· Continued growth in locally funded NHS adoption of the Genedrive® MT-RNR1 ID Kit, including the transition to Business as Usual routine clinical use in a growing number of NHS sites, continued national rollout in
· More than 13,000 neonates have been tested in clinical settings using the Genedrive® MT-RNR1 ID Kit to date, with over 40 protected from irreversible, lifelong bilateral hearing loss (frequency of 1 in 317), and the test having been used by more than 900 NICU nurses.
Genedrive® CYP2C19
· Publication of NHSE's CYP2C19 implementation plan and accompanying logistics pilot studies comparing point of care ("PoC") testing using genedrive with laboratory-based pathways. The studies demonstrated that c. 85% of patients had been discharged before laboratory-based test results were available, whereas genedrive's PoC test results were available for all patients whilst under the care of stroke team clinicians.
· Whilst subsequent commercial clarity from NHSE on the reimbursement pathway for CYP2C19 genetic testing is not yet available, the Company anticipates this to be delivered across both centralised genomic diagnostic laboratory and PoC pathways and continues to progress locally funded adoption of the Genedrive® CYP2C19 ID Kit.
· To address anticipated demand for laboratory-based CYP2C19 testing, the Company entered into a product development collaboration agreement with Thermo Fisher Scientific to develop the Genedrive® CYP2C19 HT Kit for deployment on Thermo Fisher Scientific's QuantStudioTM 5Dx, expanding the Company's addressable CYP2C19 opportunity across centralised diagnostic laboratories as well as near-patient testing pathways, with near-term focus on the
· Routine clinical use of the Genedrive® CYP2C19 ID Kit has continued at
· Continued use of the Genedrive® CYP2C19 ID Kit as a "test of change" in rural settings in
International
· Further progress across key international markets including:
o In
o In the
o In
CYP2C19 FDA 510(k) programme
· Since completion of the equity raise in
Financials
· The Board expects to report total income of approximately
· The Company completed an equity raise in
Board update
The recruitment process for a new independent Non-Executive Chairman as well as two other independent Non-Executive Directors is progressing and further announcements will be made in due course.
Outlook
The Board remains encouraged by increasing clinical adoption of both the Genedrive® CYP2C19 and MT-RNR1 ID Kits, the growing evidence base supporting point-of-care pharmacogenetic testing, and the continued progress towards wider NHS implementation. The commercial and operational progress achieved during FY26 reinforces the Board's confidence in the long-term opportunity for both products.
Looking ahead, the Company remains focused on converting commercial opportunities into routine clinical adoption, supporting the development of national commissioning and procurement pathways, expanding its presence in key international markets and advancing its
The Company continues to engage closely with NHS stakeholders, healthcare providers and international partners to support implementation of its technologies and generate additional real-world evidence demonstrating their clinical and economic value. The Board remains confident in the Company's strategy and committed to delivering innovative diagnostic solutions that improve patient outcomes while generating sustainable value for shareholders.
|
genedrive plc |
+44 (0)161 989 0245 |
|
Gino Miele: CEO / Russ Shaw: CFO |
https://investors.genedrive.com/s/e0025c
|
|
|
|
|
Peel Hunt LLP (Nominated Adviser and Broker) |
+44 (0)20 7418 8900 |
|
James Steel |
|
|
|
|
|
5654 & Company (Media & Investor Relations) |
|
|
Matthew Neal |
+44 (0)7917 800 011 |
|
Melissa Gardiner |
+44 (0)7757 697357 |
Subscribe to our news alert service: https://investors.genedrive.com/s/efea03
About genedrive plc (http://www.genedrive.com).
genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.
genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention
The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.
Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE